Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia

Chest

Volumn 119, Issue 5, 2001, Pages 1439-1448

  Dresser, Linda D ^a   Niederman, Michael S ^b   Paladino, Joseph A ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antibiotics; Community acquired pneumonia; Cost effectiveness

Indexed keywords

CEFTRIAXONE; CLARITHROMYCIN; ERYTHROMYCIN; GATIFLOXACIN;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG COST; ECONOMIC ASPECT; HOSPITAL COST; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESOURCE ALLOCATION; TREATMENT OUTCOME;

EID: 0034934856     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.119.5.1439     Document Type: Article

References (32)

1. Community-acquired pneumonia
2. Community-acquired pneumonia in adults: Guidelines for management
3. Practice guidelines for the management of community-acquired pneumonia in adults
4. Incidence of community-acquired pneumonia requiring hospitalizations: Results of a population-based active surveillance study in Ohio
5. The cost of treating community-acquired pneumonia
6. Community-acquired pneumonia: Epidemiology, etiology, treatment
7. Processes and outcomes of care for patients with community-acquired pneumonia: Results from the pneumonia patient outcomes research team (PORT) cohort study
8. Variation in length of hospital stay in patients with community-acquired pneumonia: Are shorter stays associated with worse medical outcomes?
9. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis assessment of severity initial antimicrobial therapy
10. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society
11. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital
12. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin
13. Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America
14. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584); A newly developed fluoroquinolone against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus
15. Treating community-acquired pneumonia in hospitalized patients: Gatifloxacin vs. ceftriaxone/clarithromycin
16. Evaluating the costs of levofloxacin and ceftriaxone in inpatient adults with community-acquired pneumonia
17. Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections
18. Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients
19. Cost-effectiveness comparison of sequential ofloxacin versus standard switch therapy
20. Cost-effectiveness of abbreviating the duration of intravenous antibacterial therapy with oral fluoroquinolones
21. Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia
22. Comparison of seven methods of preparing and administering small-volume injections
23. Evaluating the cost impact of intravenous antibiotic dosing frequencies
24. Microcost analysis of inpatient dispensing and administration of oral solids
25. Intravenous-to-oral antibiotic switch therapy
26. Severe community-acquired pneumonia: Assessment of severity criteria
27. A prediction rule to identify low-risk patients with community-acquired pneumonia
28. Treatment outcomes associated with community-acquired pneumonia in US hospitals: A 3, 000 patient survey
29. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia
30. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia
31. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia
32. New uses for new and old quinolones and the challenge of resistance